Exploring the MASLD CKD Socioeconomic Link

By Crystal Lubbe

April 10, 2025

How are MASLD and CKD interconnected, and what role do geography and socioeconomic factors play? A recently published article examines the relationship between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Chronic Kidney Disease (CKD) from a socioeconomic perspective. A geographical correlation exists between MASLD and CKD incidence, influenced by factors like the Socio-Demographic Index (SDI).

Key Insights in the MASLD CKD socioeconomic link

The study reveals a strong association between MASLD incidence and CKD, particularly in low SDI countries.

  • Geographical Correlation: MASLD and CKD show similar regional distributions. High incidence rates occur in North Africa and the Middle East.
  • Socioeconomic Influence: The association between MASLD and CKD varies by SDI status. Significant correlations are found in low SDI countries but not in high SDI countries.
  • Risk Factors: Metabolic risk factors like high blood pressure, fasting plasma glucose, and BMI contribute to CKD incidence variance.

Background Context

Metabolic dysfunction-associated fatty liver disease (MAFLD) and MASLD strongly link, both increasing CKD risk through shared factors such as type 2 diabetes, hypertension, obesity, and dyslipidemia. As CKD’s global burden rises, it is expected to become a leading cause of death by 2040. Socioeconomic factors significantly influence disease distribution and management, with disparities often emerging in low-income settings. For more information, refer to the source here.

Implications

The findings have significant implications for health economics and outcomes research:

  • Targeted Interventions: Public health strategies should address socioeconomic contexts to mitigate MASLD and CKD burden effectively.
  • Economic Burden: Addressing the MASLD CKD socioeconomic link could reduce healthcare costs by preventing complications and improving outcomes.
  • Equitable Health Outcomes: Understanding socioeconomic factors can help design policies promoting equitable healthcare access and reducing disparities.
Reference url

Recent Posts

Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays

By HEOR Staff Writer

January 13, 2026

Portugal's Epidyolex spending has topped €3 million since 2021, fueling debates on access to this CBD-based epilepsy drug through the National Health Service (SNS). If you're wondering how this impacts patient care and healthcare costs, the answer lies in Infarmed's nearly four-year evaluation fo...
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry Transformation
The fourth edition of the Global Pharma Executive Course runs from March to May 2026 at Portugal's Faculdade de Medicina da Universidade Católica Portuguesa and Hospital da Luz Lisboa. The course targets pharma industry leaders, as rapid changes driven by tech advances, therapeutic innovation, an...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Through Cardiometabolic ...

By HEOR Staff Writer

January 8, 2026

Navigating Growth in Latin American Pharmaceuticals In the Latin American pharmaceuticals sector, Bausch Health is strategically expanding its footprint under the leadership of Vice President Fernando Zarate. The company's operati...